Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection

Coxsackievirus B3 (CVB3) infections may cause life-threatening diseases and have no approved specific treatment. Some promising approaches to treat viral diseases include drug repurposing and combination therapy. We have selected in this study dasabuvir, an approved antiviral drug, and PSI-6206, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Olasunkanmi, Oluwatayo Israel, Zhong, Zhao-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249823/
https://www.ncbi.nlm.nih.gov/pubmed/35789934
http://dx.doi.org/10.1016/j.jve.2022.100074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249823/
https://www.ncbi.nlm.nih.gov/pubmed/35789934
http://dx.doi.org/10.1016/j.jve.2022.100074

Ejemplares similares